A combination drug trial to eradicate B-cell malignancies launched

13-Mar-2018 - Fueled by a multimillion dollar grant from the state's stem cell agency, researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined ...

New driver, target in advanced mucosal melanoma

16-Mar-2017 - Not all melanomas are created equal. While most melanomas appear on the skin as the result of sun exposure, a small subset of melanomas arise spontaneously from mucosal tissues. And while targeted treatments and immunotherapies have dramatically improved the prognosis for many patients with ...

Clinical Trial Results Show New Drug is Better for CLL Patients

08-Dec-2015 - Older adults with chronic lymphocytic leukemia may now have an alternative to toxic chemotherapy as their first treatment, according to a national study by a UR Medicine Wilmot Cancer Institute oncologist and reported in the New England Journal of Medicine. The phase 3 clinical trial compared a ...

Phase 2 Study of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Meets Primary Endpoint

19-Aug-2015 - AbbVie announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achievingoverall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review ...

European Medicines Agency recommends approval of two new treatment options for rare cancers

Imbruvica and Zydelig to be used in different forms of blood cancers

04-Aug-2014 - The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), at its July meeting, recommended granting marketing authorisations for two new medicines with novel mechanisms of action for the treatment of different forms of rare cancers of the blood. Imbruvica ...

European Medicines Agency recommends approval of Gazyvaro for chronic lymphocytic leukaemia

Medicine represents new treatment option for patients with rare life-threatening disease

28-May-2014 - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation for Gazyvaro (obinutuzumab) in combination with the cancer medicine chlorambucil for the treatment of adults with previously untreated chronic lymphocytic ...

Hybrigenics starts phase II clinical trial of inecalcitol in chronic lymphocytic leukemia

13-Sep-2012 - Hybrigenics announced the start of a phase II clinical trial of oral inecalcitol in patients with chronic lymphocytic leukemia (CLL). World-wide, about 130,000 new patients are diagnosed each year with CLL, for which there is currently no definitive cure. CLL is designated as an orphan disease in ...

NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

13-Jul-2012 - NOXXON Pharma announced the treatment of the first cohort of three chronic lymphocytic leukemia (CLL) patients in a Phase IIa clinical trial of its NOX-A12 anti-CXCL12/SDF-1 (CXC Chemokine Ligand 12 / Stromal Cell-Derived Factor-1) Spiegelmer®. CXCL12 signaling has been shown to play an important ...

GSK and Genmab Announce Results from Trial of Arzerra in Fludarabine and Alemtuzumab Refractory Chronic Lymphocytic Leukemia

10-Aug-2010 - GlaxoSmithKline (GSK) and Genmab A/S announced topline results from the concluded pivotal trial of ofatumumab in patients with fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab was given accelerated approval by the US Food and Drug Administration (FDA) on ...

Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL

09-Dec-2009 - Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) (FluCAM) to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) demonstrated that the ...